Posts tagged “Pozen”

Updated February 9, 2016

Premium Lock Pozen name disappears after merger is closed

Pozen The name Pozen has disappeared following the closing of the merger between the Chapel Hill-based pharmaceutical firm and Canada-based Tribute.

Updated August 11, 2015

Premium Lock Pozen's founder, CEO walks away with millions - and more to come

Pozen acknowledges in its latest financial report than company founder and CEO John Plachetka has already been paid millions to leave the company. And he will continue to cash out for a while with scheduled bonuses, according to his separation agreement.

Pozen CEO John Plachetka  Pozen CEO John Plachetka

August 11, 2015

Premium Lock Inside Pozen's separation agreement with its founder, CEO

Chairman, CEO John Plachetka  A filing with the SEC documents just how much and when Pozen Pharmaceuticals is paying its founder and CEO to leave the company. Here's an excerpt.

Updated June 22, 2015

Premium Lock Pozen's new CEO adds three execs to management team

Pozen Adrian Adams, the recently named chief executive officer of Chapel Hill-based Pozen, continues to put is management stamp on the company with new three appointments announced early Monday.

June 8, 2015

Premium Lock Pozen raises $350M, buys Canada firm, to base new company in Ireland

Merger  The new management team put in place at Pozen Pharmaceuticals last week is wasting no time in revamping the Chapel Hill based company. The firm has raised a $350 million commitment in capital, is buying a Canada-based drug firm, and after closing will form a new venture named Aralez that will be based in Ireland.

June 2, 2015

Premium Lock Pozen for sale? Founder, chair and CEO Plachetka retires

John Plachetka, the founder, chair and CEO of Pozen who grew the company to an IPO and oversaw development of a safer aspirin, has been replaced at the Chapel Hill company. He also won't be a member of the board. Two execs from another firm are taking over, including a CEO who has a history of leading drug companies such as Inspire, than have been acquired. On Tuesday, the new team formed a subsidiary in ireland.

Chairman, CEO John Plachetka  Chairman, CEO John Plachetka

December 30, 2014

Premium Lock Pozen, J&J subsidiary terminate drug partnership

Pozen For the second time in a month, Pozen is involved in the termination of a drug partnership. The latest involves a distribution deal for a pain reliever in South America.

December 18, 2014

Premium Lock #WTWTrends: Throwback Thursday, The Interview, 12 Days, Phononic and Pozen Trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Thursday, Dec. 18, 2014 as curated by @WRALTechWire.

December 18, 2014

Premium Lock Pozen's latest headache: Another FDA delay in drug approval

2014 is coming to a miserable close for Chapel Hill-based Pozen. After its stock was pummeled 30 percent when Pozen and drug giant Sanofi mutually terminated a $35 million drug deal earlier this month, on Wednesday Pozen disclosed another FDA delay in approval of a new pain killer.

Pain relief Pain relief

December 2, 2014

Premium Lock Bleak Monday: Loss of Sanofi deal pummels Pozen stock

Pozen CEO John Plachetka  Shares in Pozen were rocked Monday after the Chapel Hill-based firm announced the "mutually" terminated drug partnership deal with Sanofi. Shares rallied after falling as much as 30 percent. As part of the deal, Pozen does stand to benefit from some work done by Sanofi in the development of Pozen's "safer aspirin."

Updated December 1, 2014

Premium Lock Pozen stock plunges 30% after 'mutually' terminating $35M drug licensing deal with Sanofi

Pozen CEO John Plachetka  As Pozen nears possible approval of its "safer aspirin" product, the Chapel Hill-based pharmaceutical firm and drug giant Sanofi say they are terminating an agreement reached in 2013 that was worth as much as $35 million to the smaller company. The news triggered a 30 percent drop in Pozen's share price.

May 9, 2014

Premium Lock POZEN revenue up, plans to reduce R&D workforce

Pozen The pharmaceutical company's royalty revenue continues to rise and they expect a profitable year, but setbacks in drug candidates with the FDA have the company cutting staff in research and development to protect its balance sheet.

April 29, 2014

Premium Lock Domestic violence costs tech CEO his job; setback for Pozen; Duke's solar shines; new name for Cornerstone; Nokia picks CEO

Bulldog In today's Bulldog blog tech and life science roundup, check out headline news from Cornerstone Therapeutics, Nokia, Pozen, Duke Energy and a tech exec who says he was fired because of a conviction for domestic violence.

Updated March 5, 2014

Premium Lock Raleigh M2M firm sold; Metabolon's new deal; Red Hat expands 'cloud;' FDA nod for OxyBio; Pozen cuts losses; reboot costs TransEnterix

Bulldog In today's Bullbog blog rounding up the latest tech and life science news: Raleigh-based Jazz Wireless is sold; Metabolon makes a deal with Craig Venter firm; Red Hat joins AWS GovCloud; Oxygen Biotherapeutics can advance research on brain treatment; Pozen cuts its losses; and TransEnterix losses mount as company reboots.

January 3, 2014

Premium Lock In the news: Alicia Keys and Blackberry; Pozen; Hyundai and Google Glass; Facebook suit; Google cartoon patent

Bulldog Bulldog Blog: The latest technology news includes Blackberry parting ways with singer Alicia Keys; Hyundai offering Google Glass apps; Facebook faces a privacy suit over scanning of messages; and Google wins a patent for creating comic strips on social networks; Pozen promotes an executive.

December 23, 2013

Premium Lock Pozen's 'safer aspirin' delayed pending additional clinical study

Pozen will conduct a phase I trial comparing two dosages of its safer aspirin in order to answer FDA questions about its effects. Read more about the additional clinical study.

Chairman, CEO John Plachetka  Chairman, CEO John Plachetka

Updated November 19, 2013

Premium Lock Payday for Pozen as Horizon acquires U.S. rights to pain drug Vimovo

With a sales force already dedicated to selling an osteoarthritis drug, Horizon Pharma is better suited to selling Pozen's pain drug Vimovo. Read more about how Pozen benefits from the deal.

Chairman, CEO John Plachetka  Chairman, CEO John Plachetka

Updated November 19, 2013

Premium Lock Now that's a relief: Pain reliever deal means guaranteed minimum royalties to Pozen

The key to the deal for Pozen is guaranteed minimum royalty payments for Vimovo, an osteo-arthritis drug, the Chapel Hill-based company says.

Arthritis  Arthritis

November 7, 2013

Premium Lock With cardiovascular drug partnered, cancer becomes Pozen's next target

After landing Sanofi as a drug partner to commercialize its cardiovascular drug, Pozen is now pursuing a drug partner in cancer. Read why Pozen believes cancer is the next best opportunity for the company.

Diagram from Pozen presentation about PA technology Diagram from Pozen presentation about PA technology

Updated September 19, 2013

Premium Lock Is Pozen-AstraZeneca partnership unraveling? Firms amend sales-challenged arthritis drug Vimovo deal

Chapel-Hill based Pozen and AstraZeneca have amended their agreement on osteo-arthritis drug Vimovo, paving the way for what could be an unraveling of a drug partnership dating to 2006. Sales have disappointed both firms.

How Vimovo works How Vimovo works

Techwire Inside Partners
The Skinny: A Blog by Rick Smith